Dear Colleague,

On behalf of the European Uro-Oncology Group (EUOG) and the Organising Committee, we would like to cordially invite you to the 2nd International “State-of-the-Art” Conference on Prostate and Kidney Cancers which will be held in the beautiful city of Amsterdam on 26 and 27 September. We feel privileged and honoured to bring together the world’s leading experts in the field to present their expertise and current research. The two-day conference will provide a clinically-based overview of the current therapeutic dilemmas with an emphasis on the opportunities for multidisciplinary management. Topics are current controversies, recent developments in the field, and complex cases, in addition to the cutting edge research and the latest developments.

Remaining updated with advances in medicine is today becoming a major challenge. This International Conference will allow clinicians to stay up-to-date and assimilate new information in daily practice. Unlike other uro-oncological meetings, this symposium will provide a comprehensive but concise insight into the state-of-the-art approach to treating prostate and kidney cancer patients and there will be interactive discussions to engage the audience.

The meeting’s programme will appeal to the practicing physician and scientists in many ways. Essentially, oncologists will have an opportunity to meet recognized experts who will update them on both the scientific and clinical aspects of GU cancer. The update will have an immediate impact on your clinical practice or research efforts.

The target audience are academic and community urologists, radiation and medical oncologists, pathologists and other health care professionals, so please circulate this invitation to any colleagues you think may be interested in the symposium. We look forward to welcoming you to the "State-of-the-Art on Prostate and Kidney Cancers" Conference; anyone involved in the management of prostate or kidney cancer should attend this symposium and your diverse perspectives and contributions will add unmeasurable value to this international programme- so don’t miss it!

Kind regards,

On behalf of the Scientific Committee, the European Uro-Oncology Group and International Faculty:

Per-Anders Abrahamsson, SE
Celestia Higano, US
Susanne Osanto, NL
Hendrik van Poppel, BE
Joaquim Bellmunt (ES), René Bernards (NL), Johann De Bono (UK), Steven Campbell (US), Rob Coleman (UK), Jason Efstathiou (US), Tim Eisen (UK), Mark Emberton (UK), Bernard Escudier (FR), Karim Fizazi (FR), Gabriel Haas (US), Hossein Jadvar (US), Igle-J an de Jong (NL), Laurence Klotz (CAN), Pilar Laguna (NL), Alex Mottrie (BE), Peter Mulders (NL), Raymond Oyen (BE), Alain Ravaud (FR), Jack Schalken (NL), Matthew Smith (US), Lodewijk Wessels (NL), Peter Wiklund (SE).

**Venue**
InterContinental Amstel Hotel, Amsterdam
Professor Tulpplein, 1018 GX Amsterdam The Netherlands

**Link UroSource**
http://www.urosource.com/home/conference-reports/conference-reports/view/article/amsterdam-to-host-international-meeting-on-prostate-and-kidney-cancers/?tx_ttnews%5BbackPid%5D=462&cHash=bfde5d4f6b85eb20ad28060d7a059aa2

**International State-of-the Art in Prostate and Kidney Cancers Conference**
Thursday 26th September
9.20-9.30 **Welcome and Introduction**

**Chairs:** Susanne Osanto (NL) and Hendrik van Poppel (BE)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.30–9.50</td>
<td>Raymond Oyen, BE</td>
<td>Can imaging guide to assess the diagnosis?</td>
</tr>
<tr>
<td>9.50- 10.10</td>
<td>Steven Campbell, US</td>
<td>Operation time and warm ischemia: Preservation of renal function: does it matter for survival?</td>
</tr>
<tr>
<td>10.10-10.30</td>
<td>Alex Mottrie, BE</td>
<td>Robotic surgery: Nephron sparing surgery and health economics</td>
</tr>
<tr>
<td>10.30-10.50</td>
<td>Panel discussion</td>
<td>Optimal outcome determinant after surgery for kidney cancer</td>
</tr>
</tbody>
</table>

**Coffee break**

**Chairs:** Peter Mulders (NL) and Tim Eisen (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.10–11.30</td>
<td>Tim Eisen, UK</td>
<td>Tivozanib in RCC: Clinical and preclinical data</td>
</tr>
<tr>
<td>11.30–11.50</td>
<td>Alain Ravaud, FR</td>
<td>m-TOR inhibitor blockade in RCC</td>
</tr>
<tr>
<td>11.50–12.10</td>
<td>Bernard Escudier, FR</td>
<td>REVIVAL-History of Sorafenib: First TKI licensed in RCC</td>
</tr>
</tbody>
</table>

**Surgery in oligometastatic RCC**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.10–12.40</td>
<td>Steven Campbell, US</td>
<td>Pro Surgery</td>
</tr>
<tr>
<td></td>
<td>Bernard Escudier, FR</td>
<td>Con Surgery</td>
</tr>
</tbody>
</table>

**Lunch**

**Chairs:** Alain Ravaud (FR) and Pilar Laguna (NL)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45–14.00</td>
<td>Susanne Osanto, NL</td>
<td>Current and Future Treatment in RCC in perspective: New Landscape</td>
</tr>
</tbody>
</table>

**Chairs:** Per-Anders Abrahamsson (SE) and Matthew Smith (US)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00–14.20</td>
<td>Mark Emberton, UK</td>
<td>MRI detects prostate cancer better than conventional TRUS biopsy</td>
</tr>
<tr>
<td>14.20–14.40</td>
<td>Hendrik van Poppel, BE</td>
<td>Is there a place for surgery in really high risk PCA?</td>
</tr>
<tr>
<td>14.40–15.00</td>
<td>Jason Efstathiou, US</td>
<td>Contemporary precision radiotherapy</td>
</tr>
<tr>
<td>15.00–15.15</td>
<td>Hossein Jadvar, US</td>
<td>Molecular imaging in prostate cancer: what will the future bring us?</td>
</tr>
</tbody>
</table>

**Treatment of Oligometastatic Disease**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.15–15.30</td>
<td>Chairs &amp; Speakers</td>
<td>Cases</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker</td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>15.30</td>
<td>Coffee and tea break</td>
<td></td>
</tr>
<tr>
<td>15.50</td>
<td><strong>Targeting bone and bone metastases</strong></td>
<td>Rob Coleman, UK</td>
</tr>
<tr>
<td>16.10</td>
<td></td>
<td>Celestia Higano, US</td>
</tr>
<tr>
<td>16.30</td>
<td></td>
<td>Matthew Smith, US</td>
</tr>
<tr>
<td>16.50</td>
<td>Chairs &amp; Speakers</td>
<td></td>
</tr>
<tr>
<td>17.05</td>
<td><strong>Keynote lecture: Molecular Basis of Cancer</strong></td>
<td>René Bernards, NL</td>
</tr>
<tr>
<td>17.35</td>
<td><strong>Closing remarks</strong></td>
<td>Susanne Osanto, NL</td>
</tr>
<tr>
<td>17.40</td>
<td>Drinks and snacks</td>
<td></td>
</tr>
</tbody>
</table>

---

**International State-of-the-Art in Prostate and Kidney Cancers Conference**

**Friday 27th September**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td>Welcome and Introduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Per-Anders Abrahamsson (SE) and Karim Fizazi (FR)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.00</td>
<td><strong>State of the Art Lectures</strong></td>
<td>Lodewijk Wessels, NL</td>
<td>Personalized Medicine: How to Analyze the Individual Patient’s Genome</td>
</tr>
<tr>
<td>8.20</td>
<td><strong>Androgen Receptor Revisited</strong></td>
<td>Jack Schalken, NL</td>
<td>AR signaling and Importance of AR inhibition</td>
</tr>
<tr>
<td>8.40</td>
<td><strong>Metastatic Prostate Cancer</strong></td>
<td>Matthew Smith</td>
<td>Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer</td>
</tr>
<tr>
<td>9.00</td>
<td><strong>CRPC: Treatment Options in the Current Landscape</strong></td>
<td>Karim Fizazi, FR</td>
<td>Enzalutamide pre- and post-docetaxel</td>
</tr>
<tr>
<td>9.20</td>
<td></td>
<td>Johan de Bono, UK</td>
<td>Abiraterone</td>
</tr>
<tr>
<td>9.40</td>
<td></td>
<td>Matthew Smith</td>
<td>Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer</td>
</tr>
<tr>
<td>10.00</td>
<td>Chairs &amp; Speakers</td>
<td></td>
<td>Which Drug, Which Sequence ?</td>
</tr>
<tr>
<td>10.20</td>
<td><strong>Coffee break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.40</td>
<td><strong>Chairs:</strong> Hendrik van Poppel (BE) and Jason Efstathiou (US)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.40</td>
<td><strong>Contemporary Approaches: Old and Novel Concepts</strong></td>
<td>Per-Anders Abrahamsson, SE</td>
<td>Neo-adjuvant hormonal treatment in high risk PCA: Revival?</td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Mark Emberton, UK</td>
<td>MAPPED study design: a 6-month RCT to evaluate the effect of dutasteride on prostate cancer volume using MRI</td>
</tr>
<tr>
<td>11.20</td>
<td></td>
<td>Peter Wiklund, SE</td>
<td>Long-term outcome of Radical Prostatectomy or Radiotherapy in 34,515 men with prostate cancer: Swedish Registry Study</td>
</tr>
<tr>
<td>11.40</td>
<td></td>
<td>Matthew Smith</td>
<td>Novel AR inhibitor ARN-509: Preclinical, PK/PD and clinical results</td>
</tr>
<tr>
<td>12.00</td>
<td></td>
<td>Celestia Higano, US</td>
<td>Novel Immunotherapeutic approaches in Prostate Cancer</td>
</tr>
<tr>
<td>12.20</td>
<td></td>
<td>Chairs &amp; Speakers</td>
<td>Discussion</td>
</tr>
<tr>
<td>12.40</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Igle-Jan de Jong (NL) and Laurence Klotz (US)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Clinical Metastases and Response Assessment Issues in Clinical Trials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Speaker</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>13.50 - 14.10</td>
<td>Hossein Jadvar, US</td>
<td>Novel imaging techniques for detection of prostate metastases</td>
<td></td>
</tr>
<tr>
<td>14.10 - 14.30</td>
<td>Joaquim Bellmunt, ES</td>
<td>Docetaxel, Cabazitaxel and Combinations: Clinical Endpoints</td>
<td></td>
</tr>
<tr>
<td>14.30 - 14.50</td>
<td>Susanne Osanto, NL</td>
<td>Global Clinical Trial Development in Prostate Cancer</td>
<td></td>
</tr>
</tbody>
</table>

**Take Home Messages**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.50 - 15.15</td>
<td>Laurence Klotz, CAN</td>
<td>Take Home Message: Localized Prostate Cancer</td>
</tr>
</tbody>
</table>

**Adjourn**

**Accreditation**

EACCME accreditation will be requested for 12 points. The EACCME/EBU credit system is based on 1 European CME Credit (ECMEC) per hour with a maximum of 6 ECMECs for a full-day event. EACCME/EBU credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA).

**Registration**

GU-Congress@lumc.nl

Please state your specialty and an invoice for the registration fee will be send to you.

**Registration Fee**

- **Early Rate:** Before 01 June 2013: 290 EUR
- **Regular Rate:** After 01 June 2013: 360 EUR